PF-07104091 as a Single Agent and in Combination Therapy
Status:
Recruiting
Trial end date:
2026-11-12
Target enrollment:
Participant gender:
Summary
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the
Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for
PF-07104091 as a single agent in participants with small cell lung, non small cell lung, and
ovarian and breast cancers.